EL7.AI
Strategy BuilderCOT DataAdvanced NewsResearchNewEarnings CalendarEconomic Calendar
We use cookiesPrivacy Policy
EL7.AIEL7.AI

AI Financial Intelligence
Professional analysis of central bank decisions

© 2026 EL7.AI. All rights reserved.

Markets

  • News
  • Forex
  • Stocks
  • Crypto
  • Gold
  • Commodities
  • Indices
  • ETFs

Analysis

  • Fed
  • ECB
  • BLS
  • COT
  • Economic Calendar

Learn

  • Service Guide
  • Oil

Company

  • About
  • Contact
  • Data Methodology
  • AI Disclosure
  • Pricing
  • Enterprise
  • Terms
  • Privacy
  • Security
  • WhatsApp
Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Home
Stocks
Ironwood Pharmaceuticals, Inc.
IRWD

IRWD Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc. · NASDAQ
Market Closed
4.36
▲ ⁦+3.07%⁩ (+0.13)
Market Cap$717.7M
Beta0.21
52w Low52w High
1.055.78
Last Week
⁦+9.82%⁩
Last Month
⁦+6.86%⁩
Last 3 Months
⁦+31.72%⁩
Last Year
⁦+296.36%⁩
EL7 Factor Analysis
How we score this
Overall69
Strong — clearly above market medianSuper StockF 7/9DistressBetter than 69% of Market stocks, per EL7's model
FactorScoreDistributionValueAvgRank
▸
Valuation
95
5.5x▲17.6xTop tier
▸
Growth
68
26.2%▲7.1%Top tier
▸
Quality
72
—4.5%Top tier
▸
Safety
43
1.3x▲2.6xAround median
▸
Capital Return
10
—2.15%Bottom tier
▸
Momentum
78
270.9%▲2.3%Top tier
▸
Sentiment
22
2▼3Bottom tier

Frequently Asked Questions

What is Ironwood Pharmaceuticals, Inc. stock?▼

Ironwood Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.

How can I invest in Ironwood Pharmaceuticals, Inc.?▼

You can buy Ironwood Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.

What are the key metrics for evaluating Ironwood Pharmaceuticals, Inc.?▼

Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.

Does Ironwood Pharmaceuticals, Inc. pay dividends?▼

Dividend policies vary by company. Check the dividends section on the stock page for the payout history.

What are the risks of investing in Ironwood Pharmaceuticals, Inc.?▼

Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.

Fair Value
Low confidenceCurrent price$4.36
Analyst target · 2 analysts
$5.00
⁦+15%⁩
See it undervalued
Range ⁦$1.00–$18⁩
vs
DCF (estimate)
$35
⁦+703%⁩
Sees it clearly undervalued
⁦7.9⁩% discount · ⁦12⁩% growth
Bottom lineThe two methods broadly agree — estimate range ⁦$5.00–$35⁩.

Estimates — analyst targets and a simplified DCF, not investment advice.

Compare in the screener

AI analysis from the earnings call, financials and news

Analyst Consensus

This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.

Price Target· 2 analysts setting price target
$6.68
⁦+53.2%⁩
Current Price $4.36·Median $5.00
Low
$1.00
High
$18.00
Current price
$4.36
Average target
$6.68
Street summary

Ironwood Pharmaceuticals (IRWD) Price Target Review

The stock saw an 80.54% jump in its average price target over the past 30 days, rising from $3.7 to $6.68, coinciding with an increase in the number of analysts covering the stock. However, the data shows sharp and unusual dispersion in estimates, with a range between $1 and $18, reflecting a fundamental split in analytical outlook and high uncertainty regarding the company's fair valuation despite 'Buy' rating upgrades in early 2026.

As of 2026-09-03
Revisions momentum · 30d
⁦+80.5%⁩
Average rating
★ 3.75
Buy
Analyst coverage
⁦4 (+1)⁩
New coverage
Buy conviction
50%
Mixed
Target dispersion
390%
Wide
Analyst ratings over time4 analysts rating
1
1
2
Strong BuyBuyHoldSellStrong Sell
Rating trend — last 12 months3.75 → 3.75
Recent analyst moves
  • = Reiterate2026-02-26
    Jefferies
    Hold· $3.70
  • ⬆ Upgrade2026-01-05
    Craig-Hallum
    HoldBuy· $5.70
  • ⬆ Upgrade2026-01-05
    Citigroup
    Market PerformOutperform
Premium content
Key Financials

Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.

StockSector medianSector averagetypical sector range
MetricValuePosition within sectorVerdict
  • P/E (TTM)
    5.52x
    3.68x44.95x
    Very cheap
  • Forward P/E
    3.49x
    4.70x37.61x
    Very cheap
  • EV / EBITDA
    4.41x
    3.78x30.25x
    Very cheap
  • FCF Yield
    25.8%
    -145.2%7.8%
    Exceptional
  • Revenue Growth YoY
    26.2%
    -57.4%93.8%
    Above average
  • EPS Growth YoY
    2075.0%
    -159.3%129.8%
    Exceptional
  • Gross Margin
    —
    —
  • ROIC
    —
    —
  • Net Debt / EBITDA
    1.35x
    0.59x5.12x
    Low debt
  • Dividend Yield
    —
    —
  • Payout Ratio
    —
    —
  • Altman Z-Score
    -2.02
    -36.5017.81
    Above average
Financial Analysis
|